NewAmsterdam Pharma Company N.V. (NAMS)
(Real Time Quote from BATS)
$19.93 USD
-0.12 (-0.60%)
Updated May 17, 2024 03:28 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NAMS 19.93 -0.12(-0.60%)
Will NAMS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NAMS
Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Elanco Animal Health (ELAN)
NewAmsterdam Pharma Company (NAMS) Receives a Buy from RBC Capital
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
NewAmsterdam Pharma initiated with bullish view at TD Cowen, here's why
Strong Buy Rating for NewAmsterdam Pharma on Obicetrapib’s Promising Efficacy and Market Potential